Real-life experiences with galcanezumab and predictors for treatment response in Turkey.

ABSTRACT:

Background

The complexity of clinical practice extends far beyond the controlled settings of trials, and there is a need for real-world studies aimed at identifying which patients will respond to anti-CGRP monoclonal antibodies in different countries. This study aimed to investigate the efficacy and safety of galcanezumab in treating migraine in a real-life setting in Turkey, as well as identify predictors of treatment response.

Methods

A total of 476 patients who diagnosed with migraine according to ICHD-3 criteria and treated with galcanezumab by headache specialists were voluntarily participated in this cross-sectional study. Galcanezumab is indicated for the prevention of migraine in adults who have at least 4 monthly migraine days in Turkey. All patients filled out a su

SUBMITTER: Yalinay Dikmen P 

PROVIDER: S-EPMC10666377 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature